Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (21-30 of 1,622) with videos related to

Pageof 163
Sort By:
Gynecologic Oncology|June 13, 1998
"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?M Markman
Cleveland Clinic Journal of Medicine|May 23, 1998
The high cost of terminal care: balancing conflicting goalsM Markman
Lakartidningen|June 11, 1998
[Patients in health care--easy to read about rights, responsibility, ethics]B Markman
Women'S Health (London, England)|January 10, 2018
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancerMaurie Markman
Current Oncology Reports|February 10, 2018
The Requirement for Increasingly Effective Societal Cancer Control EffortsMaurie Markman
Cancer|February 23, 2007
Effect of obesity on survival in epithelial ovarian cancerMaurie Markman
Cancer|February 22, 2007
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncologyMaurie Markman
Current Oncology Reports|August 12, 2006
The "new" era of oral antineoplastic drug therapy: revisiting "old" concernsMaurie Markman
Cancer|May 9, 2007
Development of an ovarian cancer symptom index: possibilities for earlier detectionMaurie Markman
Current Oncology Reports|February 10, 2007
Care of the incarcerated cancer patientMaurie Markman
Pageof 163

Showing results (21-30 of 1,622) with videos related to

Sort By:
Pageof 163
Gynecologic Oncology|June 13, 1998
"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?M Markman
Cleveland Clinic Journal of Medicine|May 23, 1998
The high cost of terminal care: balancing conflicting goalsM Markman
Lakartidningen|June 11, 1998
[Patients in health care--easy to read about rights, responsibility, ethics]B Markman
Women'S Health (London, England)|January 10, 2018
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancerMaurie Markman
Current Oncology Reports|February 10, 2018
The Requirement for Increasingly Effective Societal Cancer Control EffortsMaurie Markman
Cancer|February 23, 2007
Effect of obesity on survival in epithelial ovarian cancerMaurie Markman
Cancer|February 22, 2007
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncologyMaurie Markman
Current Oncology Reports|August 12, 2006
The "new" era of oral antineoplastic drug therapy: revisiting "old" concernsMaurie Markman
Cancer|May 9, 2007
Development of an ovarian cancer symptom index: possibilities for earlier detectionMaurie Markman
Current Oncology Reports|February 10, 2007
Care of the incarcerated cancer patientMaurie Markman
Pageof 163